Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2008

BioFocus Inks Target Discovery Agreement in Oncology with Janssen Worth about $15.5M

  • BioFocus DPI stands to make 10.5 million, or about $15.45 million, through a deal inked with Janssen Pharmaceutica in oncology. The two-year target discovery collaboration will use an adenoviral platform from parent company, Galapagos, to identify novel drug targets.

    BioFocus DPI will perform assay development, screening of the SilenceSelect® and FLeXSelect® adenoviral libraries, and target validation.  Target discovery in in vitro assays may provide novel drug targets for cancer areas with an unmet medical need, according to the firms. 

    BioFocus DPI will receive an upfront payment of 2.9 million. Janssen will also pay additional research, acceptance, license, and development fees of up to 7.6 million should certain predetermined criteria be achieved.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »